학술논문
First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in > 2000 Patients (Pts).
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
00085472